---
title: "1315 Capital acquires Argonaut’s life sciences and diagnostics unit"
url: https://burnaze.com/article/a08b381c-75f7-4050-87c5-8964e0c8effd
source: "PE Hub"
original_url: https://www.pehub.com/1315-capital-acquires-argonauts-life-sciences-and-diagnostics-unit/
category: "Finance"
topics: ["Finance & M&A"]
published: 2026-09-10T14:18:28.000Z
modified: 2026-10-31T12:09:03.087Z
image: https://images.unsplash.com/photo-1526304640581-d334cdbbf45e?w=1600&q=80&auto=format&fit=crop
---

# 1315 Capital acquires Argonaut’s life sciences and diagnostics unit

**TL;DR:** 1315 Capital has acquired Argonaut Manufacturing Services' life sciences and diagnostics division, which will operate independently as Aluris Sciences. The acquisition does not affect Argonaut's core CDMO business, which remains owned by Telegraph Hill Partners, New Vale Capital, and management.

*originally published in PE Hub on 2026-09-10. [Read the original](https://www.pehub.com/1315-capital-acquires-argonauts-life-sciences-and-diagnostics-unit/).*

## Story

- The carve-out involves only the LSDx division; Argonaut’s core CDMO business remains owned by Telegraph Hill Partners, New Vale Capital and management.
- Aluris Sciences retains its existing staff and facilities, with no disruption to customer programs or drug product agreements.
- Argonaut will reinvest sale proceeds into its core fill-finish operations and expand its filling capacity.

1315 Capital has completed the acquisition of Argonaut Manufacturing Services’ life sciences and diagnostics division for undisclosed terms. The acquired division will operate independently as Aluris Sciences, with 1315 Capital supporting its continued growth and investment.

The transaction involved the LSDx division only, and ownership of Argonaut remains with Telegraph Hill Partners, New Vale Capital and management. Argonaut is a contract development and manufacturing organization specializing in aseptic fill-finish of high-value injectable biologics and pharmaceuticals.

Aluris Sciences, the newly independent entity, provides manufacturing solutions spanning formulation, filling, kitting, lyophilization, assembly, packaging and supply chain management. The company supports customers from pilot-stage programs through clinical, validation and commercial production.

Argonaut confirmed that all existing drug product program timelines, quality commitments and contractual obligations remain unchanged. Clients will continue to work with the same team at the same Carlsbad, California facilities, and no drug product programs, assets or regulatory filings were included in the transaction.

1315 Capital is a Philadelphia-based private investment firm with over $1 billion of assets under management. The firm provides growth capital to commercial-stage healthcare services, pharmaceutical and medtech outsourced services, and health and wellness companies.

## Entities

- private equity (topic)
- Finance (sector)
- PE Hub (publication)
- unit acquisition (topic)
- healthcare investment (topic)
- life sciences (topic)
- diagnostics (topic)
- 1315 Capital (investor)
- Argonaut Manufacturing Services (company)
- Aluris Sciences (company)
- Telegraph Hill Partners (investor)
- New Vale Capital (investor)

---
Originally reported by PE Hub (https://www.pehub.com/1315-capital-acquires-argonauts-life-sciences-and-diagnostics-unit/). Summarized by Burnaze (https://burnaze.com/article/a08b381c-75f7-4050-87c5-8964e0c8effd).